JAMP-OXCARBAZEPINE TABLET

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

OXCARBAZEPINE

Saadav alates:

JAMP PHARMA CORPORATION

ATC kood:

N03AF02

INN (Rahvusvaheline Nimetus):

OXCARBAZEPINE

Annus:

150MG

Ravimvorm:

TABLET

Koostis:

OXCARBAZEPINE 150MG

Manustamisviis:

ORAL

Ühikuid pakis:

30/100/500

Retsepti tüüp:

Prescription

Terapeutiline ala:

MISCELLANEOUS ANTICONVULSANTS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0140461001; AHFS:

Volitamisolek:

CANCELLED POST MARKET

Loa andmise kuupäev:

2022-09-06

Toote omadused

___________________________________________________________________________________________________________________
_
_Pr_
_JAMP-Oxcarbazepine _
_ _
_Page 1 of 53_
PRODUCT MONOGRAPH
PR
JAMP-OXCARBAZEPINE
Oxcarbazepine Tablets
150 mg, 300 mg and 600 mg
Manufacturer’s Standard
Antiepileptic
JAMP PHARMA CORPORATION
1380-203 NEWTON STREET
BOUCHERVILLE, QUEBEC
J4B-5H2
SUBMISSION CONTROL NO: 183866
Date of Preparation:
May 1, 2015
___________________________________________________________________________________________________________________
_
_Pr_
_JAMP-Oxcarbazepine _
_ _
_Page 2 of 53_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.......................................................
3
SUMMARY PRODUCT
INFORMATION................................................................................
3
INDICATIONS AND CLINICAL
USE......................................................................................
3
CONTRAINDICATIONS...........................................................................................................
3
WARNINGS AND
PRECAUTIONS..........................................................................................
3
ADVERSE
REACTIONS...........................................................................................................
14
DRUG
INTERACTIONS............................................................................................................
24
DOSAGE AND
ADMINISTRATION........................................................................................
26
OVERDOSAGE..........................................................................................................................
29
ACTION AND CLINICAL
PHARMACOLOGY......................................................................
29
STORAGE AND
STABILITY...................................................................................................
31
DOSAGE FORMS, COMPOSITION AND
PACKAGING.......................................................
32
PART II: SCIENTIFIC
INFORMATI